BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Somatic Therapy Market to Reach USD 12.40 Billion by 2032 at 17.5% CAGR: Coherent Market Insights

  July 1, 2025

   · 

  1 min read
• 

  Lymphoma

  Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems

  Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.

  July 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Fertility Market Size to Lead USD 85.5 Billion by 2034 Driven by Rising Demand for IVF Diagnostic

  July 1, 2025

   · 

  1 min read
• Press Releases

  NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

  July 1, 2025

   · 

  1 min read
• Press Releases

  Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

  July 1, 2025

   · 

  11 min read
• 

  Obesity

  Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start

  With PN-477, Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II trial.

  July 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  U.S. DNA Manufacturing Market Size to Reach USD 14.75 Billion by 2034

  July 1, 2025

   · 

  1 min read
• Press Releases

  Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison

  July 1, 2025

   · 

  1 min read
• 

  Rare diseases

  FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome

  The pivotal trial for Neurogene’s Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that could help ensure a broader label for the drug product, if approved, according to analysts.

  July 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Clinical Genomics Market Surges in 2025 with NABL-Accredited Molecular Labs and AI-Integrated Platforms

  July 1, 2025

   · 

  1 min read